Analyzing tumors for a particular molecular signature could help clinicians assess whether someone with melanoma is likely to benefit from immunotherapy.
April 2020. Full story at National Cancer Institute.
Analyzing tumors for a particular molecular signature could help clinicians assess whether someone with melanoma is likely to benefit from immunotherapy.
April 2020. Full story at National Cancer Institute.